Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
نویسندگان
چکیده
BACKGROUND Mineralocorticoid receptor antagonists reduce morbidity and mortality in patients with heart failure but can cause hyperkalemia, which contributes to reduced use of these drugs. Hypokalemia also leads to worse outcomes in patients with heart failure and may be attenuated by mineralocorticoid receptor antagonists. METHODS AND RESULTS We assessed incidence and predictors of hyperkalemia (potassium ≥5.5 mmol/L) and hypokalemia (potassium <3.5 mmol/L) and the relationship to outcomes in 1663 patients with class III or IV heart failure and left ventricular ejection fraction <35% randomized to treatment with spironolactone 25 mg or placebo in the Randomized Aldactone Evaluation Study (RALES) trial. All-cause mortality rates and the influence of potassium levels on the effectiveness of spironolactone were assessed in a landmark analysis and in relation to time-varying potassium levels. After 1 month, mean potassium levels increased in the spironolactone group but not in the placebo group (4.54±0.49 versus 4.28±0.50 mmol/L; P<0.001) and remained elevated during the trial. Although the extremes of hypokalemia and hyperkalemia at 4 weeks were associated with increased risk of mortality in both treatment arms, participants in the spironolactone arm had lower mortality rates at all potassium levels throughout the duration of the trial. The treatment benefit of spironolactone was maintained at least until potassium exceeded 5.5 mmol/L. CONCLUSIONS With appropriate surveillance of potassium and creatinine, the use of spironolactone was associated with less hypokalemia and improved survival in patients with severe heart failure even in the setting of moderate hyperkalemia.
منابع مشابه
Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist Vardeny et al: Spironolactone and Heart Failure
متن کامل
Role of mineralocorticoid receptors in the mediation of acute effects of hydrocortisone in isolated ischemic rat heart
Introduction: Cardiac preconditioning is an important method to reduce the damage caused by prolonged ischemia. Previous studies have shown that corticosteroids have protective effects on the heart, however at high concentrations this effect may be reduced with unknown mechanisms. We hypothesize that the contradictory effects of hydrocortisone at high concentration may be mediated via minera...
متن کاملCharacterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure
Based on the results of pivotal clinical trials showing significant reductions in mortality and morbidity in patients with mild to severe symptoms of heart failure, guidelines recommend mineralocorticoid receptor antagonist (MRA) therapy for patients with reduced left ventricular ejection fraction of ≤35% and New York Heart Association class II to IV heart failure symptoms in the absence of con...
متن کاملConsistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure.
Consistency of LaboratoryMonitoring During Initiation ofMineralocorticoid Receptor Antagonist Therapy in PatientsWithHeart Failure Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of heart failure therapy but have a risk of hyperkalemia. Clinical guidelines recommend close monitoring of renal function and electrolyte levels throughout the course of therapy.1 No large studies have...
متن کاملThe purpose of this study was to evaluate the effects of SM-368229, a novel mineralocorticoid receptor (MR) antagonist with partial agonistic activity, and spironolactone (SPI) on the systolic blood pressure (SBP) and serum potassium level in spontaneous
Title page DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. Recommended...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Circulation. Heart failure
دوره 7 4 شماره
صفحات -
تاریخ انتشار 2014